
    
      PRIMARY OBJECTIVES:

      I. To determine the maximum tolerated dose (MTD).

      SECONDARY OBJECTIVES:

      I. To further explore the safety and efficacy profile.

      OUTLINE:

      This is a dose-escalation study of lenalidomide.

      Patients receive oral lenalidomide once daily on days 1-28 and cetuximab IV once weekly over
      1-2 hours on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease
      progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up at 30 days.
    
  